Shares of Pulmonx Co. (NASDAQ:LUNG – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $15.00.
LUNG has been the subject of several recent analyst reports. Piper Sandler upped their target price on shares of Pulmonx from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, August 3rd. Craig Hallum initiated coverage on shares of Pulmonx in a research report on Tuesday. They issued a “buy” rating and a $18.00 target price for the company. Finally, Citigroup upped their target price on shares of Pulmonx from $14.00 to $16.00 in a research report on Monday, July 10th.
Insider Transactions at Pulmonx
Institutional Trading of Pulmonx
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE lifted its stake in Pulmonx by 229.9% during the first quarter. US Bancorp DE now owns 2,316 shares of the company’s stock valued at $26,000 after purchasing an additional 1,614 shares during the last quarter. Ensign Peak Advisors Inc acquired a new stake in shares of Pulmonx during the third quarter valued at approximately $30,000. State of Wyoming acquired a new stake in shares of Pulmonx during the second quarter valued at approximately $30,000. Point72 Hong Kong Ltd acquired a new stake in shares of Pulmonx during the first quarter valued at approximately $40,000. Finally, Royal Bank of Canada raised its holdings in shares of Pulmonx by 61.3% during the second quarter. Royal Bank of Canada now owns 3,092 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares during the period. 88.09% of the stock is owned by institutional investors and hedge funds.
Pulmonx Price Performance
Shares of NASDAQ:LUNG opened at $11.15 on Thursday. The company has a quick ratio of 7.62, a current ratio of 8.42 and a debt-to-equity ratio of 0.28. Pulmonx has a fifty-two week low of $4.07 and a fifty-two week high of $20.86. The firm has a 50-day simple moving average of $12.06 and a 200 day simple moving average of $11.91. The company has a market cap of $424.03 million, a PE ratio of -6.93 and a beta of 0.47.
Pulmonx (NASDAQ:LUNG – Get Free Report) last announced its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.43) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.43). Pulmonx had a negative net margin of 99.76% and a negative return on equity of 40.65%. The business had revenue of $17.20 million during the quarter, compared to the consensus estimate of $15.86 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. The company’s revenue for the quarter was up 23.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Pulmonx will post -1.69 EPS for the current year.
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
- Five stocks we like better than Pulmonx
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- These Quality Dividend Kings Grow their Dividends the Fastest
- How to Invest in Renewable Energy
- 3 Growth Stocks to Buy in September
- What is a Non-Fungible Token (NFT)? Definition and How it Works
- 3 Underappreciated Stocks with Nowhere to Go But Up
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.